NCT01066481View on ClinicalTrials.gov

A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2010

Primary Completion Date

March 31, 2012

Study Completion Date

April 30, 2012

Conditions
Alzheimer's DiseaseDementiaDimebonInvestigational Drug
Interventions
DRUG

PF-01913539 5 mg

PF-01913539 5 mg three times daily for 6 months

DRUG

PF-01913539 5 mg

PF-01913539 5 mg three times daily for 6 months

DRUG

Placebo

Placebo three times daily for 6 months

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01066481 - A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease | Biotech Hunter | Biotech Hunter